The American Heart Association will honor Dr. Annet Kirabo with the 2026 Joseph A. Vita Award at its Scientific Sessions in November, recognizing research that has fundamentally altered the understanding of hypertension. The award, presented annually to a scientist whose work has significantly advanced cardiovascular biology within the past five years, will be given during the Opening Session on Saturday, Nov. 7, in Chicago. The meeting, held Nov. 6-9, is a premier global exchange of cardiovascular science.
Dr. Kirabo, a professor of medicine at Vanderbilt Health, is internationally recognized for demonstrating that immune activation and inflammation are not merely consequences of high blood pressure but central drivers of the disease. Her team showed that lipid oxidation-derived protein adducts, formed when proteins bind to reactive molecules produced during fat oxidation, act as neoantigens. These neoantigens trigger antigen-presenting cell activation, T-cell responses, vascular dysfunction, and ultimately hypertension. This discovery, detailed in a lipid oxidation-derived protein adducts study, represented a paradigm shift in cardiovascular biology. It redefined how scientists view blood pressure regulation, moving the immune system from a bystander to a key player.
The implications are profound. By identifying specific immune pathways, such as sodium-sensing mechanisms in immune cells and reactive lipid molecules called isolevuglandins, Dr. Kirabo has uncovered potential therapeutic targets. These could lead to new treatments for hypertension and related cardiovascular and kidney diseases, conditions that affect millions worldwide and remain leading causes of death. Her laboratory now integrates immunology, vascular biology, genomics, metabolomics, and single-cell technologies to translate these fundamental findings into patient care.
Dr. Kirabo's influence extends beyond her research. She has published more than 230 scientific papers, sustained National Institutes of Health funding, and served the American Heart Association in numerous roles since 2009. She has been a member of the Council on Hypertension Communications Committee, including as chair, and has reviewed research proposals since 2017. She also serves on the editorial board of the Association's journal Hypertension and as an associate editor of Circulation Research. Her work has been featured in the Journal of the American Heart Association, among other publications.
"I am deeply honored to receive the Joseph A. Vita Award from the American Heart Association, an organization that has supported my career from my predoctoral and postdoctoral fellowships through my development as an independent investigator," said Dr. Kirabo. "Scientific discovery, mentorship and advancing new treatments for cardiovascular disease have been the primary focus of my career, and it is both rewarding and humbling to be recognized for it."
The award is named after the late Joseph A. Vita, M.D., founding editor of the Journal of the American Heart Association. Recipients are selected by the editors-in-chief of the Association's 14 peer-reviewed journals, celebrating research that transforms cardiovascular science. Dr. Kirabo's recognition underscores the growing importance of immunology in cardiovascular medicine and highlights how targeting inflammation could yield new strategies to prevent and treat hypertension, a condition that remains a global health challenge. For more information about the American Heart Association, visit heart.org and stroke.org.
